stockrowNovartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) Total debt
Novartis AG's total debt at the end of fiscal 2025 was $33.5B, up 13.3% from $29.6B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $46.3B. Over the past ten years it has ranged from $21.9B (fiscal 2015) to $36.0B (fiscal 2020); the current reading is higher than 91% of that period. Novartis AG ranks 6th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $33.5B | 13.31% |
| FY2024 | $29.6B | 20.26% |
| FY2023 | $24.6B | (5.98%) |
| FY2022 | $26.2B | (10.35%) |
| FY2021 | $29.2B | (19.00%) |
| FY2020 | $36.0B | 31.62% |
| FY2019 | $27.4B | (14.82%) |
| FY2018 | $32.1B | 12.67% |
| FY2017 | $28.5B | 19.87% |
| FY2016 | $23.8B | 8.53% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $46.3B | (1.55%) |
| Jun 2026 | $47.1B | 4.47% |
| Mar 2026 | $45.1B | 34.37% |
| Dec 2025 | $33.5B | 11.35% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ABBV AbbVie Inc. compare | $80.9B |
| PFE Pfizer Inc. compare | $62.7B |
| AMGN Amgen Inc. compare | $54.0B |
| MRK Merck & Co., Inc. compare | $51.1B |
| NVS Novartis AG | $46.3B |
| JNJ Johnson & Johnson compare | $35.8B |
| AZN AstraZeneca PLC compare | $31.4B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
| NVO Novo Nordisk A/S compare | $21.8B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on NVS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement